Review Article

Toxoplasma gondii Modulates the Host Cell Responses: An Overview of Apoptosis Pathways

Nour Mammari,1,2 Mohamad Adnan Halabi,2,3 Souha Yaacoub,2 Hilda Chlala,2 Marie-Laure Dardé,1,4 and Bertrand Courtioux1

1UMR S1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, Université de Limoges, CNRS FR 3503 GEIST, 87000 Limoges, France
2Medical Laboratory Department, Holy Family University, 5534 Batroun, Lebanon
3Mixed Research Unit National Center for Scientific Research 7276, INSERM U1262, Control of Immune Response B and Lymphoproliferation, University of Limoges, 87000 Limoges, France
4Department of Parasitology and Biological Resource Centre for Toxoplasma, University Hospital, 87000 Limoges, France

Correspondence should be addressed to Nour Mammari; nour.maamari@usf.edu.lb

Received 11 December 2018; Revised 13 March 2019; Accepted 26 March 2019; Published 4 April 2019

Academic Editor: Ceferino M. López Sánchez

Copyright © 2019 Nour Mammari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Infection with Toxoplasma gondii has a major implication in public health. Toxoplasma gondii is an obligate intracellular protozoan parasite that can infect all nucleated cells belonging to a wide range of host species. One of the particularities of this parasite is its invasion and persistence in host cells of immunocompetent people. This infection is usually asymptomatic. In immunocompromised patients, the infection is severe and symptomatic. The mechanisms by which T. gondii persists are poorly studied in humans. In mouse models, many aspects of the interaction between the parasite and the host cells are being studied. Apoptosis is one of these mechanisms that could be modulated by Toxoplasma to persist in host cells. Indeed, Toxoplasma has often been implicated in the regulation of apoptosis and viability mechanisms in both human and murine infection models. Several of these studies centered on the regulation of apoptosis pathways have revealed interference of this parasite with host cell immunity, cell signalling, and invasion mechanisms. This review provides an overview of recent studies concerning the effect of Toxoplasma on different apoptotic pathways in infected host cells.

1. Introduction

Toxoplasmosis is known to be one of the most common infections worldwide in humans and warm-blooded animals. One-third of the world’s population is infected with toxoplasmosis [1]. This parasite is able to theoretically infect all warm-blooded animals from birds to mammals. Cats, or more generally Felidae, are the only animals that allow for the sexual reproduction leading to oocyst excretion in their feces. Infection occurs by ingestion of cysts contained in parasitized meat or oocysts present in vegetables contaminated by cat feces. After an initial stage of tachyzoite proliferation and dissemination, the infection usually persists in a chronic form, following the formation of tissue cysts containing bradyzoites, especially in the brain [2] (Figure 1).

Clinical forms of toxoplasmosis in humans range from asymptomatic to lethal depending on the host’s immune response. Since its entry into the host, Toxoplasma gondii (T. gondii) triggers an immune response orchestrated by interferon-gamma (IFN-γ) secreted by T lymphocytes and natural killer cells (NK).

In the case of immunocompetent hosts, the immune response usually leads to the acquisition of protective immunity, preventing any reinfection. In case of immune deficiency, particularly in patients with acquired immune deficiency syndrome (AIDS), the bradyzoites released following cyst rupture are converted into tachyzoites, the proliferation of which is not effectively controlled by the immune response of the host, leading to encephalitis [3].

Most protozoan parasites can modulate the host cell response and apoptosis is one of the mechanisms targeted by...
these parasites. Apoptosis or programmed cell death is the process by which cells trigger their destruction. It was firstly described by Kerr et al. [4] and is an essential pathway for development and tissue homeostasis.

Unlike necrosis, no inflammatory reaction is involved during apoptosis, and the membrane integrity is preserved. This phenomenon is tightly regulated, and any imbalance can cause diseases. While excessive apoptosis can lead to degenerative diseases, a defect in apoptosis can lead to the development of autoimmune diseases or participate in carcinogenesis.

Apoptosis can be induced by many stimuli (growth factor deprivation, exposure to ultraviolet rays, or exogenous factors such as cancer). According to these signals, we can distinguish two major signalling pathways: the death receptor and the mitochondrial pathways. In addition, study of Ran and collaborators describes that *T. gondii* can stimulate apoptosis via endoplasmic reticulum (ER) stress during toxoplasmic encephalitis (TE) [5].

Most proapoptotic stimuli are associated with a permeabilization of the outer mitochondrial membrane. This process is regulated directly or indirectly by BH3- only molecules leading to the release of cytochrome c into the cytosol. Cytochrome c promotes the activation of caspases, the proteases responsible for the execution of apoptosis [6].

*Toxoplasma gondii* has been shown to modulate apoptotic responses of host cells to survive in infected cells. This differs depending on the cell types. *T. gondii* protects different cell types from apoptosis induced by a variety of proapoptotic treatments [7]. Blocking apoptosis helps the parasite to avoid rapid clearance by infected cells, which is activated by signals emitted by apoptotic cells. In contrast, *T. gondii* can initiate apoptosis in some cells and during specific stages of infection.

In PubMed, less than 100 articles have been published since 2014 on this subject. Herein we provide an overview of studies centered on the effect of *T. gondii* on the different apoptosis pathways to invade and persist in host cells.

### 2. *Toxoplasma gondii* Modulates Pathways to Invade Host Cells

Different studies performed in murine and in human cells showed that *T. gondii* modulates pathways during host invasion in a way that could have an impact on host cell apoptosis. In mice, tachyzoite proteins can react either directly by disrupting the host cell’s immune process or indirectly by affecting the regulation of the transcriptomic process in vitro [8, 9]. In human promyelocytic leukemia cells (HL-60) and human histiocytic lymphoma cells (U937), studies have shown that *Toxoplasma* which resides within the host cell in a parasitophorous vacuole (PV) can inhibit or initiate apoptosis [10]. Parasitophorous vacuole formation results from the sequential secretion of parasite secretory organelles called micronemes (MIC), rhoptries (ROP), and dense granules (GRA) [11]. These parasite-derived effectors are deeply involved in virulence and apoptosis modulation. A prominent feature of the PV is the presence of an intravacuolar network (IVN) that connects the parasites to each other and to the PV membrane [12]. A study by Lopez and collaborators shows that the IVN may have a role in immune modulation in the murine model [13]. However, the GRA6 association with the PV membrane alone promotes major histocompatibility complex I (MHC-I) antigen presentation to active CD8 T cells, but the presence of the IVN limits this action. This result is a new way to understand the immunopathogenicity regulation used by *T. gondii* [13].

A notable feature of *T. gondii* is its ability to invade and maintain host cell viability at any time during its intracellular residence [14]. In fact, it is known that proapoptotic molecules such as nitrite oxide (NO) or tumor necrosis factor α (TNFα) are produced by macrophages in response to *T. gondii* invasion [15, 16]. Exogenous NO can indeed induce egress of *T. gondii* tachyzoites from mouse peritoneal macrophages, [17] and IFN-γ can promote tachyzoite egress in murine astrocytes at 3 h after the infection via a mechanism that involves the interferon-regulated GTPase (IRG) protein Lrgm3 [18].

In mice, the majority of tachyzoite-secreted molecules are released during invasion [9]. A molecule secreted by the rhoptries of the parasite, ROP16, can perform a tyrosine phosphorylation of the signal transducer and activator of transcription STAT3 and STAT6 protein [19–21]. Alternatively, ROP16 can induce activation of macrophages at an early phase of infection by stimulating IL-4 and IL-10 expression, thus promoting a Th2- response [9, 22].

Additional effectors secreted by other parasitic organelles, the dense granules GRA15 and GRA16, are released and traffic to the host cell [23, 24], positively regulating genes responsible for the cell cycle and p53 tumor suppressor pathway [23]. GRA15 has been shown to regulate also host nuclear factor NF-κB pathways. It affects both parasite growth and cytokine levels specifically in *Toxoplasma* type II infection [22]. GRA15 has been implicated in activation of the proapoptotic pathway, activation of macrophages, and stimulation of Th1-response immunity, subsequently activating NK and Th17 cells resulting in oxidative stress [22, 25]. A recent study...
has revealed that GRA15 induces trophoblast apoptosis in vitro and causes abnormal pregnancies in mouse models [26].

In vivo GRA7 has a protective role in T. gondii infection. It induces NF-κB signaling activation during immune responses through formation of a complex with MyD88. GRA7/MyD88 complex-dependent NF-κB activation promotes the activation of TNF receptor-associated factor 6 (TRAF6) and reactive oxygen species (ROS) generation. Activation of this pathway enhances the release of inflammatory mediators, resulting in crucial protective efficacy against T. gondii infection in vivo [27]. The polymorphic rhoptry protein ROP18 is a key serine/threonine kinase that phosphorylates host proteins to modulate acute virulence, by providing a survival advantage to the infectious agent. The kinase activity of ROP18 suppresses NF-κB activation through the promotion of p65 degradation and proinflammatory cytokine suppression, in type I strains T. gondii [28]. A recent study shows that ROP18 can phosphorylate ER-associated protein called reticulin 1-C (RTNI-C) and promote ER stress-mediated apoptosis in neural cells in murine model [5].

To resist the parasite, a strong Th1 immune response and interleukin (IL)-12 activation is needed [29, 30]. This immune mechanism is based on stimulation NK and T cells, IFN-γ production, and activation of interferon-regulated GTPases (IRGs) to kill the parasite in the murine model [8]. However, in human cells, Toxoplasma utilizes iNOS to antagonize IFN-γ induced IDO1-mediated immunity against GRA15 effector which benefits parasite growth [25]. ROP16 has been implicated in the regulation of this immune response. ROP16 can stimulate secretion of a STAT3/6-dependent macrophage response that can reduce IL-12p70 synthesis [20]. Recently, another effect of ROP16 has been described, which has to do with regulation of tumor suppressor protein p53 gene transcription and translation in the human neuroblastoma cell line SH-SY5Y [31], in which ROP16 can induce activation of p53 protein, which promotes cell cycle arrest and p53-dependent apoptosis activation [32].

Another signaling pathway responsible for control of IL-12p70 synthesis is the mitogen-activated protein kinase (MAPKinase) pathway. MAPKinase pathway activation involves a series of kinases that autophosphorylate and activate each other (MAP4K, MAP3K, and MAP2K), culminating with the phosphorylation of a specific MAPK that regulates the expression of a subset of genes through activation of specific transcription factors. It has been reported that Toxoplasma is dependent on MAPKinase kinase (MKK) to induce autophosphorylation of the p38α MAPK and to produce IL-12p70 [33]. In a Th1 immune response, IL-23 and IL-12 are the most important mediators to bridge innate and adaptive immunity. In T. gondii RH strain-infected TPH-1 cells (human monocyte cells), IL-23 production is positively regulated by Phosphoinositide 2-Kinase (PI3K) and MAPK but negatively regulated by P38 MAPK. In contrast, IL-12 production is negatively regulated by PI3K and positively regulated by P38 MAPK and c-Jun N-terminal kinase (JNK) [34].

A novel dense granule molecule GRA24 has been identified. It can interact directly with p38α and lead to unusual phosphorylation of the host kinase [35]. In addition to the phosphorylation process, a recent proteomic study indicates that two proteins in the Toxoplasma motor complex are palmitoylated, glideosome associated protein (GAP45), and myosin A tail domain interacting protein (MTIP) and that palmitoylation of GAP45 and MTIP can regulate their cellular localization and function [36]. In addition, GAP45, one of the proteins that constitute the myosin XI motor complex required for motility of T. gondii, is phosphorylated at several sites. The transient phosphorylation of TgGAP45 at S163 and S167 appears to be important for glideosome assembly, and a TgGAP45 mutant in which these phosphorylation sites were mutated fails to interact with GAP50, the membrane anchor of the complex [37].

3. Toxoplasma gondii Modulates Host Cells Apoptosis

3.1. Apoptosis Pathways Targeted by T. gondii. Different studies in mouse and human cells have demonstrated that T. gondii modulates the apoptotic response of host cells, through downregulation [38] or upregulation of host-cell apoptosis [39]. The specific pathways, targeted by the parasite, may differ depending on the infection stage (acute or chronic), the virulence of the parasite strain, and the affected cell type. HSP 65 appears to contribute to immunity by preventing apoptosis of infected macrophages. A 1997 study by Hisaeda and collaborators showed that the high virulence Toxoplasma strain RH appears to have mechanisms that can enhance apoptosis in a culture of mouse peritoneal macrophages and in the mouse macrophage-derived J77A.1, namely, suppression of heat shock protein (HSP) 65 expression in infected cells [39]. A 1996 report by Khan et al. demonstrated that the avirulent Toxoplasma strain ME49 promotes apoptosis of mice CD4+ splenocytes via Fas-FasL interaction at 7 days after the infection [40]. Recently, Dincel et al. (2015) demonstrated also that this avirulent strain induces severe neurodegeneration in toxoplasmic encephalitis in mice. This severe inflammation is accompanied by a high expression of apoptosis mediators ADAMTS-13 (a metalloproteinase), caspase 3, caspase 8, caspase 9, TNFRI, and NO [41, 42]. Comparative analysis of these studies suggests that the virulent profile of the T. gondii strain is not a major determinant of the parasite’s ability to interfere with apoptotic process. Indeed infection of murine astrocytes by the highly virulent RH strain led to decreased expression of the antiapoptotic proteins survivin, p53 upregulated modulator of apoptosis (PUMA), and Bcl-2 and increased expression of the proapoptotic protein Noxa in the early stage of infection [43]. In the brain of TE mice, neuron apoptosis was noted to be a result of primary injury due to parasite burden or resulted from the secondary response to microglia activation, which promotes neuron cell damage [44]. The latter hypothesis was confirmed by the study of Luo et al., in which they found that infected microglia secreted the proinflammatory cytokines IL-1β, IL-6, TNF-α, and inducible NO synthase (iNOS). The inflammation generated is responsible for neuronal lesions in the brain of infected mice with reactivated TE [45].
Conversely, *T. gondii* has the ability to inhibit apoptosis in several murine and human host cells treated with a broad spectrum of proapoptotic stimuli [7, 38, 46, 47]. Presumably, *Toxoplasma gondii* interferes with different processes to inhibit apoptosis for maintaining chronic *Toxoplasma* infection.

### 3.1.1. Blocking Activation of Proapoptotic Proteins

In vitro studies have shown inhibition of mitochondrial cytochrome c release by virulent (type I) RH strain tachyzoites in MEFs (Mouse Embryonic Fibroblasts) [46, 48] and by avirulent (type II) NTE strain tachyzoites in human promyelocytic leukemia cells (HL-60) via a direct inhibition of caspases 3 and 9 [7]. But *Toxoplasma gondii* affects other apoptotic pathways. In the type I human B lymphoblastoid cell line (SKW6.4), the *Toxoplasma* RH strain induces an alteration of apoptosis triggered by Fas/CD95 pathway by degrading the pro-caspase 8 protein [49] (Figure 2). *T. gondii* has the ability to also downregulate TNFR1 or TNFR2 expression [50], as seen in RH-infected MRC5 human embryonic fibroblasts [50]. In addition to the major apoptotic pathways, *T. gondii* parasites have the capacity to affect other cell death pathways such as cytotoxic T lymphocytes (CTL) activities. RH-infected MLR murine T lymphoblasts and murine CD8+ T cells (M12-neo-1 cells) seem to be resistant to Perforin and Granzyme-mediated apoptosis (Figure 2). This inhibition of the apoptotic activity of CTLs by *T. gondii* infection [38, 49, 51] may involve a direct link between the inhibition of apoptosis and the association between the *T. gondii* vacuolar membrane and host cell mitochondria [52, 53]. Additionally, *Toxoplasma* interference with apoptosis may extend to targeting of the stage of DNA degradation. *Toxoplasma gondii* affects PARP expression in murine macrophage cells (RAW264.7 cells) infected by the avirulent NTE strain of *Toxoplasma* (Figure 2), decreasing PARP expression within 10 min and suppressing within 1 h of infection [54]. In addition, the atypical *Toxoplasma* TgCtwh3 can activate phosphorylation of STAT3 in infected human macrophages. This activation induces an overexpression of miR-17-92-miRNAs that inhibit the proapoptotic protein Bim, leading to the survival of the macrophage infected by this atypical strain [55]. The polymorphic form of ROP16 produced by this strain is similar to that produced by the type I *Toxoplasma* strain RH, so authors suggested that this ROP16-activated macrophage survival mechanism could be similar to that exerted by the canonical type I *Toxoplasma* strain [55].

The growth factors G-CSF and GM-CSF also seem to be targeted by *T. gondii* to manipulate apoptosis. Channon and collaborators demonstrated that both G-CSF and GM-CSF secreted by human fibroblastic cells infected with the avirulent PLK strain of *Toxoplasma* inhibited apoptosis of human neutrophils [56], and therefore *T. gondii*-induced G-CSF and GM-CSF secretion can promote neutrophil survival. Recently, Wang et al. demonstrated that the RH strain induces apoptosis in neural stem cells (NSCs) via the endoplasmic reticulum pathway. This finding was confirmed by a high expression of C/EBP homologue protein (CHOP), caspase 12, and activation of JNK pathway in NSCs cocultured with tachyzoites of RH *Toxoplasma* strain [57].

### 3.1.2. Upregulating Antiapoptotic Proteins

Upregulation of antiapoptotic proteins includes expression of antiapoptotic Bcl-2 family [47, 58], downregulation of proapoptotic Bax proteins [48] (Figure 2), and the prevention of Bax/Bak activation by BH3-only family members [59]. In addition, the HSP70 family, an endogenous pleiotropic inhibitor of apoptotic cell death has been reported to also regulate apoptosis by influencing the apoptosis promoting activity of mitochondria [60, 61]. Heat shock is capable of inducing apoptosis and causes a cell initiate synthesis of heat-shock proteins (HSPs). HSP70 derived from *T. gondii*-infected cells has been shown to be important for the control of host
immune responses. Indeed, injection with *Toxoplasma gondii* HSP70 caused an important reduction of parasite burden in various organs of B6 and BALB/c mice during both acute and chronic phases of toxoplasmosis [62]. Bcl-2 and HSP70 expressed by *Toxoplasma*-infected human monocyte infected cells (TH1) inhibited the mitochondrial permeability transition pore, blocked the release of both cytochrome c and apoptosis inducing factor protein (AIF) from the mitochondria, and inhibited ATP-mediated procaspase 3/9 [58] (Figure 2).

The antiapoptotic serine protease inhibitors Serpin B3 and B4 are significantly induced in acute mononuclear leukemia-derived macrophages of the THP-1 lineage infected with the RH strain of *T. gondii* through activation of STAT6[63], and Serpin B3 and B4 may thus function as cellular factors involved in the parasite's regulation of the apoptosis pathway [64].

3.2. Apoptosis Signaling Pathway Targeted by *T. gondii*

3.2.1. NF-κB Pathway. The NF-κB pathway consists of a family of primary transcription nuclear factors, conserved in all multicellular eukaryotic organisms and expressed in almost all cell types. These factors regulate the expression of antiapoptotic, proinflammatory cytokines. NF-κB signaling is extremely important to the host immune response against *Toxoplasma* infection and regulates the direction of the host's immunity.

It has been described that *T. gondii* regulates apoptosis pathways through A1-a, an antiapoptosis member of the Bcl-2 family. This process may be an important proinflammatory event in acute host responses. It leads to an increase in parasite burden in the nonapoptotic cells [65]. The *Toxoplasma* RH strain upregulates also the expression of Mcl-1 (Figure 2) (another antiapoptotic Bcl-2 family member) and inhibitors of apoptosis (IAP) [7, 66]. Many of the cellular IAPs are known to be under NF-κB regulation [67, 68], which promotes the host prosurvival machinery and proinflammatory expression proteins in mouse NIH 3T3 Balb/c fibroblasts [47]. The NF-κB pathway plays a crucial role in modulating both innate and adaptive immune responses. NF-κB activation is extensively considered to play an antiapoptotic function in cellular responses to diverse injurious stimuli [69]. In bone marrow-derived murine macrophages infected by the RH strain, p50, p65, and RelB were observed in response to parasite challenge during *in vitro* and *in vivo* studies [70, 71]. The importance of the NF-κB pathway for regulating the immune response to survive acute *Toxoplasma* infection [72] was confirmed in a study using mice deficient in Bcl-3, a protein involved in the regulation of NF-κB [73]. Using DNA arrays, expression of Bfl-1, IAP2, and TNFR1 was elevated over threefold in wild-type cells compared to mice deficient in the p65 subunit of NF-κB [66]. The parasite-mediated induction of Bfl-1 might prevent host cell death primarily through the regulation of mitochondrial events such as membrane depolarization, cytochrome c release, and caspase-9 activation [74, 75] (Figure 2). IAP activation (1 and 2) enhances T cells activation [76]. A lack of NF-κB activity could have an important effect in enhancing the expression level of survival genes [66]. In addition, *T. gondii*-infected mouse spleen cells display activation of antiapoptotic Bcl-2 family members but not proapoptotic pathways. The resistance of *T. gondii*-infected mouse spleen cells to apoptosis was attributed to the prevention of caspase-3 activity and PARP activation. This apoptosis inhibition was regulated by the activation of NF-κB that promotes transcription of antiapoptotic genes (Figure 2). In this case, the expression of NF-κB is correlated with antiapoptotic protein expression after *T. gondii* infection [77]. A recent study has shown that the NF-κB pathway can be implicated in the activation of the apoptotic process in human leukaemia cell line. The *T. gondii* ME-49 strain can inhibit NF-κB activation via upregulation of the protein levels of the A20 ubiquitin chain enzyme that inhibits NF-κB by inhibiting the TCR signaling pathway in infected Jurkat T-cells and Molt-4 T-cells [78].

3.2.2. MAPKinase (Mitogen-Activated Protein Kinase) Pathways. In addition to the NF-κB pathway, MAPKinase pathways are also involved in activation of both innate and acquired immune responses during infection by *T. gondii* [77]. *T. gondii* induces P38 MAPKinase autophosphorylation in mouse macrophages, promoting IL-12 production [79, 80] (Figure 2). The *Toxoplasma* mitogen-activated protein (Tg-MAPK) has been identified as a virulent factor regulating host immunity response and *Toxoplasma* tachyzoite proliferation [81]. The Tg-MAPK controls IFN-γ-mediated iNOS expression and NO production and promotes activation of host cell p38 MAPK activation, thereby limiting host iNOS production [81] (Figure 2). The inhibition of apoptosis observed in BeWo cells (human placental cells) after infection with RH strain is associated with the increased phosphorylation of the antiapoptotic ERK1/2 protein [82]. Recently, the study by Cao and collaborators demonstrated that in African green monkey kidney cells (Vero cells) infected by type I *Toxoplasma* strain, the *Toxoplasma* MAPK1, the orthologue of mammalian MAPK P38 α, is involved in bradyzoite differentiation and in asexual development of *T. gondii* [83]. *Toxoplasma* can also interact with p38α via GRA24, promoting host kinase activation, leading in most cases to the host death [84].

3.2.3. JNKinase (c-Jun N-Terminal Kinases) Pathways. The JNKinase pathway is also involved in activation and/or inhibition of apoptosis mechanisms during infection by *T. gondii*. The role of JNK, as either a proapoptotic or prosurvival mediator, is dependent upon the magnitude and duration of JNK activation and appears to be cell-type specific [85], while the transcription factor NF-κB has recently been shown to negatively regulate JNK activation [86, 87]. Carmen et al. [88] showed that the JNK pathway does not involve the NF-κB signaling pathway *Toxoplasma*-infected human Hela cells. In infected mouse bone marrow-derived macrophages and human peripheral blood monocytes, *Toxoplasma* induced the B7-2 protein, which initiates T cell proliferation. B7-2 production is mediated via the JNK signaling pathway. The effective role of JNK signaling pathway is not yet clear during *Toxoplasma* infection [89].
The JNK pathway is implicated also in the upregulation of c-Myc (host cell growth) in *Toxoplasma*-infected human foreskin fibroblasts (HFFs). It is reported that *T. gondii* may be manipulating c-Myc to prevent both host cell and parasite apoptosis, enabling *Toxoplasma* to survive and proliferate inside the host. Similarly, c-Myc-mediated regulation of host immune function could serve as protection from host immune recognition [90]. The ASK1/JNK is also involved in activation of apoptosis trophoblasts in the mouse model during acute *T. gondii* infection [91].

3.2.4. PI3K/PKB/Akt Pathways. Phosphoinositide 3 kinase (PI3K) is a family of signal transducing enzymes implicated in various cellular functions, such as growth, proliferation, and cell survival, ensuring the maintenance of homeostasis. This pathway is activated during *T. gondii* infection and is essential for the invasion and proliferation of the parasite in the host cell. The phosphoinositide 3-kinase pathway and the immediate downstream effector protein kinase B (PKB/Akt) play important roles in cell survival and apoptosis inhibition. *Toxoplasma gondii* activates these pathways in a dose-dependent manner via toll-like receptors TLR2 and TLR4 [92]. PI3k / AKT decreases the expression of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4 (NOX4) gene, which then reduces the amount of Reactive Oxygen Species (ROS) in the infected cell and consequently provides a suitable environment for the proliferation of *T. gondii* in host cell [93]. ROS plays an essential role in the immune response against pathogens, such as bacteria and intracellular parasites. One of the major sources of ROS is NADPH and more specifically NOX 4. Moreover, it was described that Nox4-mediated ROS generation plays a central role in macrophage migration inhibitory factor (MIF) production and resistance to *T. gondii* infection in the mouse model [94]. Likewise, this pathway is involved in the regulation of the secretion of IL-23 and IL-12 in *Toxoplasma*-infected Jurkat cells [95]. This suggests that both the IL-23 and IL-12 are implicated in the resistance of *Toxoplasma* infection [34].

It was reported that *Toxoplasma* infection of mouse macrophages activates PKB/Akt *in vivo* and *in vitro*. This pathway promotes inhibition of the apoptosis challenge via host G protein-dependent PI 3-kinase signalling [96]. In addition, *T. gondii* inhibits apoptosis mechanism also via this signaling pathway in THP-1 cells and splenocytes. The phosphorylation of AKT protein promotes phosphorylation of Bad protein which can prevent apoptosis activation by blocking Bax translocation, cytochrome c release, and caspase 3/9 activation [97] (Figure 2).

4. Conclusion

*Toxoplasma gondii* manipulates many signalling pathways intended for host defense to achieve persistence in host cells. Among the host signalling pathways targeted by *Toxoplasma* are apoptotic pathways. This response induces, in most cases, a local inflammatory reaction as in the case of TE. Most studies are described in the mouse model. It would be important to determine the difference of *T. gondii* strains effect on the inhibition of proapoptotic pathways and activation of antiapoptotic pathways in *in vitro* coculture system of different cells that can be infected by *T. gondii* [98]. This model allows us to study the interaction of different host cells in the presence of the parasite. Thus, the caspase-dependent apoptotic pathway has been well studied. Further research on the effect of *T. gondii* virulence proteins could be focused on pathways not depending on caspase. New molecular biology and proteomic technics will permit the identification of the activation, inhibition, and interaction of, and between, several proteins responsible for the signalling pathways involved in the persistence of *T. gondii* in host cells.

Conlicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

[1] S. K. Halonen and L. M. Weiss, “Toxoplasmosis,” in Neuroparasitology and Tropical Neurology, vol. 114 of Handbook of Clinical Neurology, pp. 125–145, Elsevier, 2013.
[2] A. M. Sullivan, X. Zhao, Y. Suzuki, E. Ochiai, S. Crutcher, and M. A. Gilchrist, “Evidence for finely-regulated asynchronous growth of Toxoplasma gondii cysts based on data-driven model selection,” PLoS Computational Biology, vol. 9, no. 11, p. e1003283, 2013.
[3] S. Kamerkar and P. H. Davis, “Toxoplasma on the brain: understanding host-pathogen interactions in chronic CNS infection,” Journal of Parasitology Research, vol. 2012, Article ID 589295, 10 pages, 2012.
[4] J. F. Kerr, A. H. Wyllie, and A. R. Currie, “Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics,” British Journal of Cancer, vol. 26, no. 4, pp. 239–257, 1972.
[5] R. An, Y. Tang, L. Chen et al., “Encephalitis is mediated by ROP18 of Toxoplasma gondii, a severe pathogen in AIDS patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 115, no. 23, pp. E5344–E5352, 2018.
[6] N. N. Danial and S. J. Korsmeyer, “Cell death: critical control points,” Cell, vol. 116, no. 2, pp. 205–219, 2004.
[7] S. Goebl, U. Gross, and C. G. K. Lüder, “Inhibition of host cell apoptosis by Toxoplasma gondii is accompanied by reduced activation of the caspase cascade and alterations of poly(ADP-ribose) polymerase expression,” Journal of Cell Science, vol. 114, no. 19, pp. 3495–3505, 2001.
[8] J. C. Howard, J. P. Hunn, and T. Steinfeldt, “The IRG protein-based resistance mechanism in mice and its relation to virulence in Toxoplasma gondii,” Current Opinion in Microbiology, vol. 14, no. 4, pp. 414–421, 2011.
[9] C. A. Hunter and L. D. Sibley, “Modulation of innate immunity by Toxoplasma gondii virulence effectors,” Nature Reviews Microbiology, vol. 10, no. 11, pp. 766–778, 2012.
[10] C. G. K. Lüder, U. Gross, and M. F. Lopes, “Intracellular protozoan parasites and apoptosis: diverse strategies to modulate parasite-host interactions,” Trends in Parasitology, vol. 17, no. 10, pp. 480–486, 2001.
[11] L. D. Sibley, “Invasion and intracellular survival by protozoan parasites,” Immunological Reviews, vol. 240, no. 1, pp. 72–91, 2011.

[12] M.-F. Cesbron-Delawa, C. Gendrin, L. Travier, P. Ruffiot, and C. Mercier, “Apicomplexa in mammalian cells: trafficking to the parasitophorous vacuole,” Traffic, vol. 9, no. 5, pp. 657–664, 2008.

[13] J. Lopez, A. Bittame, C. Massera et al., “Intravacuolar membranes regulate CD8 T cell recognition of membrane-bound Toxoplasma gondii protective antigen,” Cell Reports, vol. 13, no. 10, pp. 2273–2286, 2015.

[14] T. Tomita, T. Yamada, L. M. Weiss, and A. Orlofsky, “Externally triggered egress is the major fate of Toxoplasma gondii during acute infection,” The Journal of Immunology, vol. 183, no. 10, pp. 6667–6680, 2009.

[15] J. E. Albina, J. A. Abate, and W. L. Henry Jr., “Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation: role of IFN-γ in the induction of the nitric oxide-synthesizing pathway,” The Journal of Immunology, vol. 147, no. 1, pp. 144–148, 1991.

[16] M. Higuchi and B. B. Aggarwal, “Differential roles of two types of the TNF receptor in TNF-induced cytotoxicity, DNA fragmentation, and differentiation,” The Journal of Immunology, vol. 152, no. 8, pp. 4017–4025, 1994.

[17] Y.-S. Ji, X.-M. Sun, X.-Y. Liu, and X. Suo, “Toxoplasma gondii: effects of exogenous nitric oxide on egress of tachyzoites from infected macrophages,” Experimental Parasitology, vol. 133, no. 1, pp. 70–74, 2013.

[18] T. Melzer, A. Duffy, L. M. Weiss, and S. K. Halonen, “The gamma interferon (IFN-γ)-inducible GTP-binding protein IGTP is necessary for Toxoplasma vacuolar disruption and induces parasite egression in IFN-γ-stimulated astrocytes,” Infection and Immunity, vol. 76, no. 11, pp. 4883–4894, 2008.

[19] J. P. J. Saeij, S. Coller, J. P. Boyle, M. E. Jerome, M. W. White, and J. C. Boothroyd, “Toxoplasma co-opts host gene expression by injection of a polymorphic kinase homologue,” Nature, vol. 445, no. 7125, pp. 324–327, 2007.

[20] B. A. Butcher, B. A. Fox, L. M. Rommereim et al., “Toxoplasma gondii rhoptry kinase rop16 activates stat3 and stat6 resulting in cytokine inhibition and arginase-1-dependent growth control,” PLoS Pathogens, vol. 7, no. 9, p. e1002236, 2011.

[21] Y.-C. Ong, M. L. Reese, and J. C. Boothroyd, “Toxoplasma rhoptry protein 16 (ROP16) subverts host function by direct tyrosine phosphorylation of STAT6,” The Journal of Biological Chemistry, vol. 285, no. 37, pp. 28731–28740, 2010.

[22] E. E. Rosowski, D. Lu, L. Julien et al., “Strain-specific activation of the NF-xB pathway by GRA15, a novel Toxoplasma gondii dense granule protein,” The Journal of Experimental Medicine, vol. 206, no. 1, pp. 195–212, 2011.

[23] A. Bougdour, E. Durandau, M.-P. Brenier-Pinchart et al., “Host cell subversion by Toxoplasma GRA16, an exported dense granule protein that targets the host cell nucleus and alters gene expression,” Cell Host & Microbe, vol. 13, no. 4, pp. 489–500, 2013.

[24] K. D. C. Jensen, K. Hu, R. J. Whitmarsh et al., “Toxoplasma gondii rhoptry 16 kinase promotes host resistance to oral infection and intestinal inflammation only in the context of the dense granule protein gra15,” Infection and Immunity, vol. 81, no. 6, pp. 2156–2167, 2013.

[25] H. Bando, Y. Lee, N. Sakaguchi et al., “Inducible nitric oxide synthase is a key host factor for Toxoplasma GRA15-dependent disruption of the gamma interferon-induced antiparasitic human response,” mBio, vol. 9, no. 5, 2018.

[26] C. Wang, W. Cheng, Q. Yu et al., “Toxoplasma Chinese 1 strain of WHΔrop16/113/g1a15I1 genetic background contributes to abnormal pregnant outcomes in murine model,” Frontiers in Immunology, vol. 9, p. 1222, 2018.

[27] C.-S. Yang, J.-M. Yuk, Y.-H. Lee, and E.-K. Jo, “Toxoplasma gondii GRA7-induced TRAF6 activation contributes to host protective immunity,” Infection and Immunity, vol. 84, no. 1, pp. 339–350, 2015.

[28] J. Du, R. An, L. Chen et al., “Toxoplasma gondii virulence factor rop18 inhibits the host NF-κB pathway by promoting p65 degradation,” The Journal of Biological Chemistry, vol. 289, no. 18, pp. 12578–12592, 2014.

[29] R. S. Goldszmid, P. Caspar, A. Rivollier et al., “NK cell-derived interferon-γ orchestrates cellular dynamics and the differentiation of monocytes into dendritic cells at the site of infection,” Immunity, vol. 36, no. 6, pp. 1047–1059, 2012.

[30] K. W. Tosh, L. Mittereder, S. Bonne-Annee et al., “The IL-12 response of primary human dendritic cells and monocytes to toxoplasma gondii is stimulated by phagocytosis of live parasites rather than host cell invasion,” The Journal of Immunology, vol. 196, no. 1, pp. 345–356, 2016.

[31] W. Fan, S. Chang, X. Shan et al., “Transcriptional profile of SH-SY5Y human neuroblastoma cells transfected by Toxoplasma rhoptry protein 16,” Molecular Medicine Reports, vol. 14, no. 5, pp. 4099–4108, 2016.

[32] H. Iwasa, T. Kudo, S. Maimaiti et al., “The RASSF6 tumor suppressor protein regulates apoptosis and the cell cycle via MDM2 protein and p53 protein,” The Journal of Biological Chemistry, vol. 288, no. 42, pp. 30320–30329, 2013.

[33] W. Im, H. Kim, D. Yun et al., “Cytokine reporter mouse system for screening novel IL12/23 p40-inducing compounds,” Molecules and Cells, vol. 20, no. 2, pp. 288–296, 2005.

[34] J. Quan, J. Chu, J. Kwon et al., “Intracellular networks of the PI3K/AKT and MAPK pathways for regulating Toxoplasma gondii-induced IL-23 and IL-12 production in human THP-1 cells,” PLoS ONE, vol. 10, no. 11, p. e0141550, 2015.

[35] L. Braun, M.-P. Brenier-Pinchart, M. Yogavel et al., “A Toxoplasma dense granule protein, GRA24, modulates the early immune response to infection by promoting a direct and sustained host p38 MAPK activation,” The Journal of Experimental Medicine, vol. 210, no. 10, pp. 2071–2086, 2013.

[36] M. L. Jones, M. O. Collins, D. Goulding, J. S. Choudhary, and J. C. Rayner, “Analysis of protein palmitoylation reveals a pervasive role in Plasmodium development and pathogenesis,” Cell Host & Microbe, vol. 12, no. 2, pp. 246–258, 2012.

[37] S. D. Gilk, E. Gaskins, G. E. Ward, and C. J. M. Beckers, “GAP45 phosphorylation controls assembly of the Toxoplasma myosin XIV complex,” Eukaryotic Cell, vol. 8, no. 2, pp. 190–196, 2009.

[38] P. B. Nash, M. B. Burner, P. R. Leon, P. Clarke, R. C. Duke, and T. J. Curriel, “Toxoplasma gondii-infected cells are resistant to multiple inducers of apoptosis,” The Journal of Immunology, vol. 160, no. 4, pp. 1824–1830, 1998.

[39] H. Hidaeda, T. Sakai, H. Ishikawa et al., “Heat shock protein 65 induced by gammadelta T cells prevents apoptosis of macrophages and contributes to host defense in mice infected with Toxoplasma gondii,” The Journal of Immunology, vol. 159, no. 5, pp. 2375–2381, 1997.
[40] I. A. Khan, T. Matsuura, and L. H. Kasper, “Activation-mediated CD4+ T cell unresponsiveness during acute Toxoplasma gondii infection in mice,” *International Immunology*, vol. 8, no. 6, pp. 887–896, 1996.

[41] G. C. Dinkel and H. T. Atmaca, “Increased expressions of ADAMTS-13 and apoptosis contribute to neuropathology during Toxoplasma gondii encephalitis in mice,” *Neuropathology*, vol. 36, no. 3, pp. 211–226, 2016.

[42] G. C. Dinkel and H. T. Atmaca, “Nitric oxide production increases during Toxoplasma gondii encephalitis in mice,” *Experimental Parasitology*, vol. 156, pp. 104–112, 2015.

[43] C. O. Contreras-Ochoa, A. Lagunas-Martínez, J. Belkind-Gerson, J. Díaz-Chávez, and D. Correa, “Toxoplasma gondii invasion and replication within neonate mouse astrocytes and changes in apoptosis related molecules,” *Experimental Parasitology*, vol. 134, no. 2, pp. 256–265, 2013.

[44] U. Händel, A. Brunn, K. Drögemüller, W. Müller, M. Deckert, and D. Schlüter, “Neuronal gp30 expression is crucial to prevent neuronal loss, hyperinflammation, and lethal course of murine toxoplasma encephalitis,” *The American Journal of Pathology*, vol. 181, no. 1, pp. 163–173, 2012.

[45] Q. Luo, L. Sun, Q.-Q. Tian et al., “Effect of culture supernatant of Toxoplasma gondii on the proliferation and apoptosis of BGC-823 cells,” *Chinese Journal of Parasitology & Parasitic Diseases*, vol. 32, no. 2, pp. 123–127, 2014.

[46] S. Goebel, C. G. K. Lüder, and U. Gross, “Invasion by toxoplasma gondii protects human-derived HL-60 cells from actinomycin D induced apoptosis,” *Medical Microbiology and Immunology*, vol. 187, no. 4, pp. 221–226, 1999.

[47] T. M. Payne, R. E. Molestina, and A. P. Sinai, “Inhibition of caspase activation and a requirement for NF-κB function in the Toxoplasma gondii-mediated blockade of host apoptosis,” *Journal of Cell Science*, vol. 116, no. 21, pp. 4345–4358, 2003.

[48] J. C. Carmen, L. Hardi, and A. P. Sinai, “Toxoplasma gondii inhibits ultraviolet light-induced apoptosis through multiple interactions with the mitochondrion-dependent programmed cell death pathway,” *Cellular Microbiology*, vol. 8, no. 2, pp. 301–315, 2006.

[49] P. Vutova, M. Wirth, D. Hippe et al., “Toxoplasma gondii inhibits Fas/CD95-triggered cell death by inducing aberrant processing and degradation of caspase 8,” *Cellular Microbiology*, vol. 9, no. 6, pp. 1556–1570, 2007.

[50] D. Derouich-Guergour, D. Aldebert, I. Vigan et al., “Toxoplasma gondii infection can regulate the expression of tumour necrosis factor-α receptors on human cells in vitro,” *Parasite Immunology*, vol. 24, no. 5, pp. 271–279, 2002.

[51] T. Yamada, T. Tomita, L. M. Weiss, and A. Orlofsky, “Toxoplasma gondii inhibits granzyme B-mediated apoptosis by the inhibition of granzyme B function in host cells,” *International Journal for Parasitology*, vol. 41, no. 6, pp. 595–607, 2011.

[52] A. P. Sinai, P. Webster, and K. A. Joiner, “Association of host cell endoplasmic reticulum and mitochondria with the Toxoplasma gondii parasitophorous vacuole membrane: a high affinity interaction,” *Journal of Cell Science*, vol. 110, no. 17, pp. 2117–2128, 1997.

[53] A. P. Sinai and K. A. Joiner, “The Toxoplasma gondii protein ROP2 mediates host organelle association with the parasitophorous vacuole membrane,” *The Journal of Cell Biology*, vol. 154, no. 1, pp. 95–108, 2001.

[54] A. Gais, N. Beinert, U. Gross, and C. G. K. Lüder, “Transient inhibition of poly(ADP-ribose) polymerase expression and activity by Toxoplasma gondii is dispensable for parasite-mediated blockade of host cell apoptosis and intracellular parasite replication,” *Microbes and Infection*, vol. 10, no. 4, pp. 358–366, 2008.

[55] Y. Cai, H. Chen, X. Mo et al., “Toxoplasma gondii inhibits apoptosis via a novel STAT3-miR-17-92-Bim pathway in macrophages,” *Cellular Signalling*, vol. 26, no. 6, pp. 1204–1212, 2014.

[56] J. Y. Channon, K. A. Miselis, L. A. Minnis, C. Dutta, and L. H. Kasper, “Toxoplasma gondii induces granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor secretion by human fibroblasts: Implications for neutrophil apoptosis,” *Infection and Immunity*, vol. 70, no. 11, pp. 6048–6057, 2002.

[57] T. Wang, J. Zhou, X. Gan et al., “Toxoplasma gondii induce apoptosis of neural stem cells via endoplasmic reticulum stress pathway,” *Parasitology*, vol. 141, no. 7, pp. 988–995, 2014.

[58] I.-Y. Hwang, J. H. Quan, M.-H. Ahn et al., “Toxoplasma gondii infection inhibits the mitochondrial apoptosis through induction of Bcl-2 and HSP70,” *Parasitology Research*, vol. 107, no. 6, pp. 1313–1321, 2010.

[59] D. Hippe, A. Gais, U. Gross, and C. G. K. Lüder, “Modulation of caspase activation by Toxoplasma gondii,” *Methods in Molecular Biology*, vol. 470, pp. 275–288, 2009.

[60] C. Didelot, E. Schmitt, M. Brunet, L. Maingret, A. Parcellier, and C. Garrido, “Heat shock proteins: endogenous modulators of apoptotic cell death,” in *Handbook of Experimental Pharmacology*, vol. 172, pp. 171–198, 2006.

[61] M. A. Yenari and R. M. Sapolsky, “Gene therapy in neurological disease,” *Methods in Molecular Medicine*, vol. 104, pp. 75–88, 2005.

[62] R. M. Mohamed, F. Aosai, M. Chen et al., “Induction of protective immunity by DNA vaccination with Toxoplasma gondii HSP70, HSP30 and SAG1 genes,” *Vaccine*, vol. 21, no. 22, pp. 2852–2861, 2003.

[63] H.-J. Ahn, J. Y. Kim, K.-J. Ryu, and H.-W. Nam, “STAT6 activation by Toxoplasma gondii infection induces the expression of Th2 C-C chemokine ligands and B clade serine protease inhibitors in macrophage,” *Parasitology Research*, vol. 105, no. 5, pp. 1445–1453, 2009.

[64] K. J. Song, H.-J. Ann, and H.-W. Nam, “Anti-apoptotic effects of SERPIN B3 and B4 via STAT6 activation in macrophages after infection with Toxoplasma gondii,” *The Korean Journal of Parasitology*, vol. 50, no. 1, pp. 1–6, 2012.

[65] A. Orlofsky, L. M. Weiss, N. Kawachi, and M. B. Prystowsky, “Deficiency in the anti-apoptotic protein A1-a results in a diminished acute inflammatory response,” *The Journal of Immunology*, vol. 168, no. 4, pp. 1840–1846, 2002.

[66] R. E. Molestina, T. M. Payne, I. Coppens, and A. P. Sinai, “Activation of NF-κB by Toxoplasma gondii correlates with increased expression of antiapoptotic genes and localization of phosphorylated IκB to the parasitophorous vacuole membrane,” *Journal of Cell Science*, vol. 116, no. 21, pp. 4359–4371, 2003.

[67] C. Stehlik, R. De Martin, B. R. Binder, and J. Lipp, “Cytokine induced expression of porcine inhibitor of apoptosis protein (iap) family member is regulated by NF-κB(α),” *Biochemical and Biophysical Research Communications*, vol. 243, no. 3, pp. 827–832, 1998.

[68] X. Wang and W. A. Frazier, “The thrombospondin receptor CD47 (IAP) modulates and associates with α2β1 integrin in...
vascular smooth muscle cells,” *Molecular Biology of the Cell (MBoC)*, vol. 9, no. 4, pp. 865–874, 1998.

[69] M. Karin and A. Lin, “NF-κB at the crossroads of life and death,” *Nature Immunology*, vol. 3, no. 3, pp. 221–227, 2002.

[70] J. Caamano, J. Alexander, L. Craig, R. Bravo, and C. A. Hunter, “The NF-kappa B family member RelB is required for innate and adaptive immunity to Toxoplasma gondii,” *Journal of Immunology*, vol. 163, no. 8, pp. 4453–4461, 1999.

[71] S. Shapira, K. Speirs, A. Gerstein, J. Caamano, and C. Hunter, “Suppression of NF-κB activation by infection with Toxoplasma gondii,” *The Journal of Infectious Diseases*, vol. 185, Suppl 1, pp. S66–S72, 2002.

[72] J. H. Caamaño, C. A. Rizzo, S. K. Durham et al., “Nuclear factor (NF)-κB2 (p100/p52) is required for normal splenic microarchitecture and B cell–mediated immune responses,” *The Journal of Experimental Medicine*, vol. 187, no. 2, pp. 185–196, 1998.

[73] G. Franzoso, L. Carlson, T. Scharton-Kersten et al., “Critical roles for the Bcl-3 oncprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions,” *Immunology*, vol. 6, no. 4, pp. 479–490, 1997.

[74] M. Chen, F. Aosal, H.-S. Mun, K. Norose, H. Hata, and A. Yano, “Anti-HSP70 autoantibody formation by B-1 cells in Toxoplasma gondii-infected mice,” *Infection and Immunity*, vol. 68, no. 9, pp. 4839–4899, 2000.

[75] Y. H. Lee, J. Y. Channon, T. Matsuura, J. D. Schwartzman, D.-W. Shin, and L. H. Kasper, “Functional and quantitative analysis of splenic T cell immune responses following oral *Toxoplasma gondii* infection in mice,” *Experimental Parasitology*, vol. 91, no. 3, pp. 212–221, 1999.

[76] M. L. Giardino Torchia, D. B. Conze, and J. D. Ashwell, “c-IAP1 and c-IAP2 redundancy differs between T and B cells,” *PLoS ONE*, vol. 8, no. 6, e66613, 2013.

[77] J. Kim, M. Ahn, H. Jun, J. Jung, J. Ryu, and D. Min, “Toxoplasma gondii inhibits apoptosis in infected cells by caspase inactivation and NF-κB activation,” *Yonsei Medical Journal*, vol. 47, no. 6, pp. 862–869, 2006.

[78] Q. Chen, M. Pang, X. Ye, G. Yang, and C. Lin, “The Toxoplasma gondii ME-49 strain upregulates levels of A20 that inhibit NF-κB activation and promotes apoptosis in human leukemia T-cell lines,” *Parasites & Vectors*, vol. 11, no. 1, p. 305, 2018.

[79] S.-K. Kim and J. C. Boothroyd, “Stage-specific expression of surface antigens by Toxoplasma gondii as a mechanism to facilitate parasite persistence,” *The Journal of Immunology*, vol. 174, no. 12, pp. 8038–8048, 2005.

[80] N. J. Mason, J. Fiore, T. Kobayashi, K. S. Masek, Y. Choi, and C. A. Hunter, “TRAF6-dependent mitogen-activated protein kinase activation differentially regulates the production of interleukin-12 by macrophages in response to Toxoplasma gondii,” *Infection and Immunity*, vol. 72, no. 10, pp. 5662–5667, 2004.

[81] M. J. Brumlík, S. Pandeveswa, S. M. Ludwig et al., “TgMAPK1 is a Toxoplasma gondii MAP kinase that hijacks host MKK3 signals to regulate virulence and interferon-γ-mediated nitric oxide production,” *Experimental Parasitology*, vol. 134, no. 3, pp. 389–399, 2013.

[82] M. B. Angeloni, P. M. Gixwell, P. S. Franco et al., “Differential apoptosis in BeWo cells after infection with highly (RH) or moderately (ME49) virulent strains of Toxoplasma gondii is related to the cytokine profile secreted, the death receptor Fas expression and phosphorylated ERK1/2 expression,” *Placenta*, vol. 34, no. II, pp. 973–982, 2013.

[83] L. Cao, Z. Wang, S. Wang et al., “Deletion of mitogen-activated protein kinase 1 inhibits development and growth of Toxoplasma gondii,” *Parasitology Research*, vol. 115, no. 2, pp. 797–805, 2016.

[84] E. Pellegrini, A. Palencia, L. Braun et al., “Structural basis for the subversion of MAP kinase signaling by an intrinsically disordered parasite secreted agonist,” *Structure*, vol. 25, no. 1, pp. 16–26, 2017.

[85] T. M. Johnson, Z. Rajfur, K. Jacobson, and C. J. Beckers, “Immobilization of the type XIV myosin complex in Toxoplasma gondii,” *Molecular Biology of the Cell (MBoC)*, vol. 18, no. 8, pp. 3039–3046, 2007.

[86] G. Tang, Y. Minemoto, B. Dibling et al., “Inhibition of JNK activation through NF-κB target genes,” *Nature*, vol. 414, no. 6861, pp. 313–317, 2001.

[87] C. Bubici, S. Papa, C. G. Pham, F. Zazzeroni, and G. Franzoso, “The NF-kappaB-mediated control of ROS and JNK signaling,” *Histology and Histopathology*, vol. 21, no. 1, pp. 69–80, 2006.

[88] J. C. Carmen, R. C. Southard, and A. P. Sinai, “The complexity of signaling in host-pathogen interactions revealed by the Toxoplasma gondii-dependent modulation of JNK phosphorylation,” *Experimental Cell Research*, vol. 314, no. 20, pp. 3724–3736, 2008.

[89] P. Morgado, Y.-C. Ong, J. C. Boothroyd, and M. B. Lodoen, “Toxoplasma gondii induces B7-2 expression through activation of JNK signal transduction,” *Infection and Immunity*, vol. 79, no. II, pp. 4401–4412, 2011.

[90] M. Franco, A. J. Shastri, and J. C. Boothroyd, “Infection by Toxoplasma gondii specifically induces host c-Myc and the genes this pivotal transcription factor regulates,” *Eukaryotic Cell*, vol. 13, no. 4, pp. 483–493, 2014.

[91] X. Xu, T. Liu, A. Zhang et al., “Reactive oxygen species-triggered trophoblast apoptosis is initiated by endoplasmic reticulum stress via activation of caspase-12, CHOP, and the JNK pathway in Toxoplasma gondii infection in mice,” *Infection and Immunity*, vol. 80, no. 6, pp. 2121–2132, 2012.

[92] E. B. Borovik, I. P. Lebedeva, and B. N. Semenov, “The organization of the rehabilitation of work capacity in patients and the disabled in foreign countries,” *Voprosy Kurortologii, Fizioterapii, I Lechebnoi? Fizicheskoi? Kultury*, no. 1, pp. 68–72, 1989.

[93] W. Zhou, J. Quan, Y. Lee, D. Shin, and G. Cha, “Toxoplasma gondii proliferation require down-regulation of host Nox4 expression via activation of PI3 kinase/Akt signaling pathway,” *PLoS ONE*, vol. 8, no. 6, e66306, 2013.

[94] J. H. Kim, J. Lee, S.-J. Bae et al., “NADPH oxidase 4 is required for the generation of macrophage migration inhibitor factor and host defense against Toxoplasma gondii infection,” *Scientific Reports*, vol. 7, no. 1, p. 6361, 2017.

[95] H. A. H. A. Ismail, B.-H. Kang, J.-S. Kim et al., “IL-12 and IL-23 production in Toxoplasma gondii- or LPS-treated jurkat T cells via PI3K and MAPK signaling pathways,” *The Korean Journal of Parasitology*, vol. 55, no. 6, pp. 613–622, 2017.

[96] L. Kim and E. Y. Denkers, “Toxoplasma gondii triggers Gi-dependent PI 3-kinase signaling required for inhibition of host cell apoptosis,” *Journal of Cell Science*, vol. 119, no. 10, pp. 2119–2126, 2006.

[97] J.-H. Quan, G.-H. Cha, W. Zhou, J.-Q. Chu, Y. Nishikawa, and Y.-H. Lee, “Involvement of PI 3-kinase/Akt-dependent Bad phosphorylation in Toxoplasma gondii-mediated inhibition of host cell apoptosis,” *Experimental Parasitology*, vol. 133, no. 4, pp. 462–471, 2013.
[98] A. Y. Lupatov, R. A. Poltavtseva, O. A. Bystrykh, K. N. Yarygin, and G. T. Sukhikh, “Neural stem/progenitor cells maintained in vitro under different culture conditions alter differentiation capacity of monocytes to generate dendritic cells,” *Journal of Stem Cells and Regenerative Medicine*, vol. 13, no. 2, pp. 54–61, 2017.